Home » Topics » BioWorld Science

BioWorld Science
RSS

Doxil/Caelyx evaluated in phase II for advanced breast cancer

Nov. 24, 1997

NK3 antagonist demonstrates intestinal antiinflammatory activity

Nov. 24, 1997

FDA advisory committee recommends approval of Rocephin for AOM

Nov. 24, 1997

Role of substance P in PTH secretion described

Nov. 24, 1997

New NK1 antagonist from Novartis

Nov. 24, 1997

Six-month trial of lamivudine for chronic hepatitis B

Nov. 24, 1997

Phase I trial of multiple-dose IDEC-C2B8 in NHL

Nov. 24, 1997

Role of complement in mast cell-dependent natural immunity

Nov. 24, 1997

Favorable results obtained in pediatric study of Neuprex

Nov. 24, 1997

Brain GABA receptor ligands prepared at Neurogen

Nov. 24, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...